Drug repurposing against coronavirus disease 2019 (COVID-19):A review
- Author:
Lianxiang LUO
1
,
2
;
Qin QIU
;
Fangfang HUANG
;
Kaifeng LIU
;
Yongqi LAN
;
Xiaoling LI
;
Yuge HUANG
;
Liao CUI
;
Hui LUO
Author Information
1. Marine Biomedical Research Institute,Guangdong Medical University,Zhanjiang,524023,Guangdong,China
2. Marine Medical Research Institute of Zhanjiang,Zhanjiang,524023,Guangdong,China
- Keywords:
Drug repurposing;
COVID-19;
SARS-CoV-2;
Virtual screening;
3C-like protease
- From:
Journal of Pharmaceutical Analysis
2021;11(6):683-690
- CountryChina
- Language:Chinese
-
Abstract:
Since December 2019,severe acute respiratory syndrome coronavirus 2 has been found to be the culprit in the coronavirus disease 2019 (COVID-19),causing a global pandemic.Despite the existence of many vaccine programs,the number of confirmed cases and fatalities due to COVID-19 is still increasing.Furthermore,a number of variants have been reported.Because of the absence of approved anti-coronavirus drugs,the treatment and management of COVID-19 has become a global challenge.Under these circumstances,drug repurposing is an effective method to identify candidate drugs with a shorter cycle of clinical trials.Here,we summarize the current status of the application of drug repurposing in COVID-19,including drug repurposing based on virtual computer screening,network pharmacology,and bioactivity,which may be a beneficial COVID-19 treatment.
